Researchers uncover two-drug combo that halts the growth of cancer cells

(UT Southwestern Medical Center) UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Authors: Gunawan I, Hatta M, Benyamin AF, Islam AA Abstract OBJECTIVE: Hypoxia-associated biomarkers profiling may provide information for prognosis, staging, and subsequent therapy. We aim to evaluate whether the quantitative gene and protein expression of hypoxic response tumor markers - carbonic anhydrase IX (CAIX) and hypoxia- inducible factor 1 alpha (HIF1A) - may have a role in predicting survival in advanced breast cancer of Indonesian population. METHODS: Tumor tissues and peripheral blood samples were collected from treatment - naïve locally advanced (LABC) or metastatic breast cancer patients (MB...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Enhertu (fam-trastuzumab deruxtecan-nxki) is approved to treat unresectable or metastatic HER2-positive breast cancer after other treatments have been unsuccessful.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research
ConclusionsThe study of breast cancer perfusion shows a higher BF in large tumors and in tumors with lymph node involvement, not paralleled by similar modifications in tumor global metabolism. In addition, the observed correlation between the perfusion heterogeneity and the metabolism heterogeneity suggests that tumor perfusion and consequently the process of tumor angiogenesis might be involved in the metabolism heterogeneity previously shown in BC.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
(American Association for Cancer Research) A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types, according to results from a phase I study.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conditions:   Locally Advanced Solid Tumor;   Metastatic Cancer;   Solid Tumor;   HER2-positive Gastric Cancer;   HER2-positive Metastatic Breast Cancer Interventions:   Drug: ACE1702;   Drug: Cyclophosphamide;   Drug: Fludarabine Sponsor:   Acepodia Biotech Inc. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
ConclusionOur results suggest that breast cancer dynamically changes during disease progression, and growth rate of the cancer cells is associated with distinct transcriptional profiles.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Despite great progress in surgery and other treatments, the prognosis of patients with esophageal squamous cell carcinoma (ESCC) is still very poor. HER2 has strong therapeutic implications in certain cancers,...
Source: Diagnostic Pathology - Category: Pathology Authors: Tags: Research Source Type: research
This study aimed to explore the applicability of kinetic modelling and parametric image analysis for absolute quantification of68Ga-ABY-025 uptake and HER2-receptor expression and how that relates to static SUVs.MethodsDynamic68Ga-ABY-025 PET of the upper abdomen was performed 0-45  min post-injection in 16 patients with metastatic breast cancer. Five patients underwent two examinations to test reproducibility. Parametric images of tracer delivery (K1) and irreversible binding (Ki) were created with an irreversible two-tissue compartment model and Patlak graphical analysis using an image-derived input function from ...
Source: EJNMMI Research - Category: Radiology Source Type: research
Abstract Kinase-targeted therapy has been widely used as a lifesaving strategy for cancer patients. However, many patients treated with targeted cancer drugs are clinically observed to rapidly develop acquired resistance. Kinase gatekeeper mutation is one of the most chief factors contributing to the resistance, which modulates the accessibility of kinase's ATP-binding pocket. Previously, the pan-kinase inhibitor Staurosporine and its analogs (termed as Staralogs) have been reported to exhibit wild-type sparing selectivity for some kinase gatekeeper mutants, such as EGFR T790M, Her2 T798M and cSrc T338M. Here, we ...
Source: Amino Acids - Category: Biochemistry Authors: Tags: Amino Acids Source Type: research
This study provides novel lncRNAs as potential biomarkers for the therapeutic and prognostic classification of different breast cancer subtypes. PMID: 32190687 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
More News: Cancer | Cancer & Oncology | HER2